G:BOX Chemiluminescence Imager is used at Prestigious Research Institute To Rapidly Determine the Pre-clinical Potential of Anti-Cancer Compounds
Publication date: 29 September 2009
Author:
Tagged with: David Mincher, Edinburgh Napier University, Laura Sullivan, Syngene
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is proud to announce its G:BOX chemiluminescence imaging system is being used by scientists at one of Scotland’s top Universities, Edinburgh Napier University in Edinburgh to accurately determine the effectiveness of novel anti-cancer therapies.
Researchers in the School of Life Sciences at Edinburgh Napier University are using the G:BOX chemiluminescence imaging system to image agarose gels of DNA stained with Ethidium Bromide to determine the effects that new anti-topoisomerase compounds have on topoisomerase action during the cell cycle. The researchers are also using the system to image gelatin zymograms to discover the effects that compounds have on the modulation of matrix metalloproteinases. The scientists believe their research could help develop novel drugs to treat a variety of cancers.
Dr David Mincher, Reader in Experimental Chemotherapy at Edinburgh Napier explained:” In recent years, the action of topoisomerases and matrix metalloproteinases have been implicated in many cancers. Therefore, we are looking at a number of New Chemical Entities and pro-drugs which target these proteins but to determine the efficacy of these compounds we have to be able to precisely quantify their effects on the expression of DNA or proteins. Since we need high levels of accuracy and reproducibility in our results we installed a G:BOX imaging system just over a year ago to work alongside our other Syngene image analyser and the new system has been absolutely invaluable for this project.”
Laura Sullivan, Syngene’s Divisional Manager added: “We are delighted Edinburgh Napier University has chosen to install another Syngene system and to see how much the G:BOX system is contributing to this exciting research. The work at Edinburgh Napier is an excellent endorsement of the system’s ability to rapidly produce and analyse images of applications as diverse as 1D gels, zymograms and autoradiograms and means G:BOX chemiluminescence imaging systems can be confidently used in many drug discovery programmes where accurately quantifying DNA and protein amounts is critical.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content